hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-03. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
==== Data Protection Commission (Europe) ==== In September 2021, the Ireland Data Protection Commission (DPC) launched investigations into TikTok concerning the protection of minors' data and transfers of personal data to China. The Irish DPC became the lead agency to handle such matters after TikTok established an office in the country, taking over investigations started by Dutch and Italian authorities. In September 2023, the DPC fined TikTok €345 million for violations of the General Data Protection Regulation (GDPR) vis-à-vis the mishandling of children data. In April 2025, the Ireland DPC fined TikTok over €500 million for illegally sending European user data to China. In July 2025, the DPC opened a new investigation into TikTok for unauthorized transfers of user data to China.
=== Category:EC 1.8 (act on a sulfur group of donors) === Category:EC 1.8.1 (with NAD+ or NADP+ as acceptor) Glutathione reductase EC 1.8.1.7 Thioredoxin reductase EC 1.8.1.9 Category:EC 1.8.2 (with a cytochrome as acceptor) Category:EC 1.8.3 (with oxygen as acceptor) Sulfite oxidase EC 1.8.3.1 Category:EC 1.8.4 (with a disulfide as acceptor) Category:EC 1.8.5 (with a quinone or similar compound as acceptor) Category:EC 1.8.6 deleted, included in EC 2.5.1.18 Category:EC 1.8.7 (with an iron–sulfur protein as acceptor) Category:EC 1.8.98 (with other, known, acceptors) Category:EC 1.8.99 (with other acceptors)
=== Further reading === Voet D and Voet J (2004). Biochemistry (3rd ed.). John Wiley and Sons Inc. pp. 1321–1322 and 1342–1343. Hale WG, Margham JP, Saunders VA eds (1995) Collins Dictionary of Biology, (2nd ed) Shine-Dalgarno (SD) sequence. p 565. Lewin, B. (1994) Genes V. Oxford University Press. pp 179, 269. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD (1994) The Molecular Biology of the Cell (3rd ed.) pp 237, 461. Malys N, McCarthy JE (2011). "Translation initiation: variations in the mechanism can be anticipated". Cellular and Molecular Life Sciences. 68 (6): 991–1003. doi:10.1007/s00018-010-0588-z. PMC 11115079. PMID 21076851. S2CID 31720000. Cicek Mustafa, Mutlu Ozal, Erdemir Aysegul, Ozkan Ebru, Saricay Yunus, Turgut-Balik Dilek (2013). "Single Mutation in Shine-Dalgarno-Like Sequence Present in the Amino Terminal of Lactate Dehydrogenase of Plasmodium Effects the Production of an Eukaryotic Protein Expressed in a Prokaryotic System". Molecular Biotechnology. 54 (2): 602–608. doi:10.1007/s12033-012-9602-z. hdl:11511/55531. PMID 23011788. S2CID 45230872.{{cite journal}}: CS1 maint: multiple names: authors list (link)
His stated goal for the company was to add 1,000 new locations outside of the Northeastern United States by the end of 2020 and to have a revenue increase of 3 percent for stores open a year or longer. In late 2018, Dunkin' installed espresso machines at all possible locations and launched espresso products using a new recipe. In June 2019, Dunkin' partnered with Grubhub to begin the rollout of its new Dunkin' Delivers service. Later in July 2019, Dunkin' partnered with Beyond Meat to introduce a meatless breakfast sandwich in Manhattan, becoming the first U.S. restaurant brand to serve Beyond Sausage. The sandwich launched nationally later in 2019. In September 2019, the New York attorney general's office alleged in a lawsuit that Dunkin' mishandled a series of cyberattacks that were directed at customers using the Dunkin' mobile app. These attacks took place in early 2015 and thousands of usernames and passwords were stolen. The state lawsuit alleges that Dunkin' employees knew about these attacks, but failed to take appropriate action. In October 2020, Dunkin' Brands stated that the company was in conversation with Inspire Brands, a private equity-backed company, negotiating to sell the company. They agreed to a deal that was announced on Saturday, October 31, 2020. Inspire Brands bought Dunkin' Brands for $11.3 billion, which included Dunkin' Brands' debt that Inspire Brands would be paying off. Inspire paid $106.50 in cash for each of Dunkin' Brands' shares.
Consumption of breakfast cereal is under preliminary research for the potential to improve nutrition and affect chronic diseases. Regular breakfast cereal consumption is associated with less risk of being overweight or obese and high-fiber breakfast cereals are associated with a lower risk of diabetes. Fortified breakfast cereals with iron can be an effective option to reduce risk of anemia in children.
Sources: en.wikipedia.org
organizing international conferences and workshops in mass spectrometry improving mass spectrometry education standardizing terminology in the field aiding in the dissemination of mass spectrometry through publications
=== Felim Bichan === Felim Bichan (Andrew Buchan) is a Scottish hedge fund manager and initially Pierpoint's biggest client with a decades-long client relationship with Eric. A firm, principled man who ascended from humble beginnings, Felim initially cuts ties with Eric and Pierpoint after Eric drunkenly makes offensive comments in front of Felim's wife. On Eric's orders, Harper attempts to coax Felim back to the firm, but Felim gently warns Harper not to fall prey to Eric's malign influence. In series 2, Felim returns as Pierpoint's client so long as Harper act the intermediary between him and Eric. Harper, however, blows off a client meeting with Eric and Felim to meet with notorious independent investor Jesse Bloom, who she is courting as a client. Felim is initially the anchor on a $3.3 billion block trade for shares of healthcare startup Rican, with Eric promising him pre-buy stock options. Felim, however, pulls out of the trade after Harper misses the client meeting, as it reaffirms his distrust of Eric, and Harper sells the shares to Bloom at the last minute instead. Felim, Jesse, Harper and Eric attend a duck shoot in Wales for Rican investors, which Pierpoint initially organized to celebrate Felim's planned purchase of Rican stock. Felim and Jesse remain at odds since Felim rejects his modest beginnings while Jesse embraces his, and Felim chastises Harper for gravitating towards bullies. Jesse later injures Felim's face with shrapnel while trying to shoot a rare pheasant.
A study of children admitted to hospital in Rawalpindi, Pakistan, found that 52.1% of the bottles their caregivers considered clean were actually contaminated. This occurred even though caregivers reportedly followed many of the recommended cleaning practices for cleaning and sterilizing bottles. The most common mistake was to boil the bottles for less than the minimum time recommended by WHO. Research into the preparation of infant formula in South Korea indicates significant levels of contamination can be transmitted through the handling of spoons and other utensils. Spoons, after being touched, were often left in the formula container, allowing bacteria to spread to the formula in the container. C. sakazakii, S. enterica, and S. aureus, all of which are potentially fatal, were able to surviving for weeks in contaminated infant formula. Understanding how recommendations are interpreted is important: in one study, leaving a bottle in water that had been previously boiled in a kettle was believed to be "boiling" the bottle. Researchers emphasize that health providers need to better educate caregivers; and that practical methods of bottle hygiene need to be suited to use in field settings. For example, in Peru, easy-to-adopt practices like using a bottle brush and detergent gave greater advantages than difficult-to-achieve procedures like boiling a bottle. WHO (which strongly recommends breastfeeding) notes that in cases where bottle feeding is to occur, much better education is needed on how to use bottles.
== Causes == Myxedema coma represents an extreme or decompensated form of hypothyroidism. Most cases occur in patients who have been previously diagnosed with hypothyroidism, yet in some cases, hypothyroidism may not have been previously identified. Common precipitating factors of myxedema coma include:
Later that day, Afghan Taliban officials announced that they had launched a new wave of attacks against Pakistani border guards in the border areas of Khost and Paktia provinces. The fighting later spread to the border areas of Kunar and Nangarhar provinces. The same day, Pakistani Taliban leader Noor Wali Mehsud ordered the group's fighters to intensify and systematically carry out attacks in support of the Afghan Taliban. He also instructed them to post video evidence of their attacks directly on social media without prior permission. Jamaat ul Ahrar, an offshoot of the Pakistani Taliban, also ordered its fighters to intensify attacks in Pakistan in response to Pakistani airstrikes against the Afghan Taliban. It also said that its fighters would step up attacks in the provinces of Sindh and Punjab. Following these orders, militant attacks on police stations and outposts were reported in Peshawar, Bannu, Hangu, and Mattani, injuring a police officer and a civilian.
Sources: en.wikipedia.org
Dry-aged beef is beef that has been hung or placed on a rack to dry for several weeks. After the animal is slaughtered and cleaned, it is hung as a full or half carcass. Primal (large distinct sections) or sub primal cuts, such as strip loins, rib eyes, and sirloin, are placed in a refrigerator unit, also known as a "hot box". This process involves considerable expense, as the beef must be stored near freezing temperatures. Subprimal cuts can be dry aged on racks either in specially climate-controlled coolers or within a moisture-permeable drybag. Moreover, only the higher grades of meat can be dry aged, as the process requires meat with a large, evenly distributed fat content. Because of this, dry-aged beef is seldom available outside of steak restaurants and upscale butcher shops or groceries. The key effect of dry aging is the concentration and saturation of the natural flavour, as well as the tenderization of the meat texture. The process changes beef by two means. Firstly, moisture is evaporated from the muscle. The resulting process of desiccation creates a greater concentration of beef flavour and taste. Secondly, the beef's natural enzymes break down the connective tissue in the muscle, which leads to more tender beef. The process of dry-aging usually also promotes growth of certain fungal (mold) species on the external surface of the meat. This does not cause spoilage, but rather forms an external "crust" on the meat's surface, which is trimmed off when the meat is prepared for cooking.
Polypyrrole (PPy) is an organic polymer obtained by oxidative polymerization of pyrrole. It is a solid with the formula H(C4H2NH)nH. It is an intrinsically conducting polymer, used in electronics, optical, biological and medical fields.
The Paleolithic ( PAY-lee-oh-LITH-ik, PAL-ee-), or Old Stone Age, is a period in human prehistory distinguished by the original development of stone tools. It represents almost the entire period of human prehistoric technology, extending from the earliest known use of stone tools by hominins, c. 3.3 million years ago, to the end of the Pleistocene, c. 11,650 cal BP. The Paleolithic Age in Europe preceded the Mesolithic Age, although the date of the transition varies geographically by several thousand years. During the Paleolithic Age, hominins grouped together in small societies such as bands and subsisted by gathering plants, fishing, and hunting or scavenging wild animals. The Paleolithic Age is characterized by the use of knapped stone tools, although at the time humans also used wood and bone tools. Other organic commodities were adapted for use as tools, including leather and vegetable fibers; however, due to rapid decomposition, these have not survived to any great degree. About 50,000 years ago, a marked increase in the diversity of artifacts occurred. In Africa, bone artifacts and the first art appear in the archaeological record. The first evidence of human fishing is also noted, from artifacts in places such as Blombos Cave in South Africa. Archaeologists classify artifacts of the last 50,000 years into many different categories, such as projectile points, engraving tools, sharp knife blades, and drilling and piercing tools.
== Activities == The activity in Chromatography spans HPLC, LC/MS, FPLC, MPLC - GC, GC/MS, GPC, GFC - RMN - AA, IR, ICP, UV – SPE. Interchim notably introduced new generation silica chromatography media (UptiSphere that has become a standard worldwide, Strategy, Atoll). The activity in Fine Chemistry deals with compounds libraries (Chirals, Fluorines, Building blocks for Combi-Chemistry) and flash chromatography. Interchim developed a unique flash chromatography system (PuriFlashEvo430 - integrated functions). The activity in BioSciences focuses on Immunodetection, Biochemistry, Electrophoresis and Cell Assays. Interchim manufactures protein assays (BC Assay, Coo Assay), superior fluorescent dyes known as FluoProbes, Cell Assays reagents and kits (i.e. FluoProbes indicators, high sensitive viability assay UptiBlue) and an innovate transfection agent UptiFectin.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.